| Memantine in moderate-to-severe Alzheimer's disease B Reisberg, R Doody, A Stöffler, F Schmitt, S Ferris, HJ Möbius New England Journal of Medicine 348 (14), 1333-1341, 2003 | 2864 | 2003 |
| A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) G Wilcock, HJ Möbius, A Stöffler International clinical psychopharmacology 17 (6), 297-305, 2002 | 567 | 2002 |
| Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease—a unified glutamatergic hypothesis on the mechanism of action W Danysz, CG Parsons, HJÖ MÖbius, A StÖffler, GÜ Quack Neurotoxicity research 2 (2), 85-97, 2000 | 467 | 2000 |
| Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial S Gauthier, HH Feldman, LS Schneider, GK Wilcock, GB Frisoni, ... The Lancet 388 (10062), 2873-2884, 2016 | 421 | 2016 |
| Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials B Winblad, RW Jones, Y Wirth, A Stöffler, HJ Möbius Dementia and geriatric cognitive disorders 24 (1), 20-27, 2007 | 372 | 2007 |
| Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies S Gauthier, Y Wirth, HJ Möbius International Journal of Geriatric Psychiatry: A journal of the psychiatry …, 2005 | 317 | 2005 |
| A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease B Reisberg, R Doody, A Stöffler, F Schmitt, S Ferris, HJ Möbius Archives of neurology 63 (1), 49-54, 2006 | 245 | 2006 |
| Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease A Wimo, B Winblad, A Stöffler, Y Wirth, HJ Möbius Pharmacoeconomics 21, 327-340, 2003 | 240 | 2003 |
| Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group P Robert, KL Lanctôt, L Agüera-Ortiz, P Aalten, F Bremond, ... European Psychiatry 54, 71-76, 2018 | 226 | 2018 |
| Potential of low dose leuco-methylthioninium bis (hydromethanesulphonate)(LMTM) monotherapy for treatment of mild Alzheimer’s disease: Cohort analysis as modified primary … GK Wilcock, S Gauthier, GB Frisoni, J Jia, JH Hardlund, HJ Moebius, ... Journal of Alzheimer's disease 61 (1), 435-457, 2018 | 206 | 2018 |
| Randomized, double-blind, placebo-controlled study of encenicline, an α7 nicotinic acetylcholine receptor agonist, as a treatment for cognitive impairment in schizophrenia RSE Keefe, HA Meltzer, N Dgetluck, M Gawryl, G Koenig, HJ Moebius, ... Neuropsychopharmacology 40 (13), 3053-3060, 2015 | 154 | 2015 |
| No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use GL Wenk, G Quack, HJ Moebius, W Danysz Life Sciences 66 (12), 1079-1083, 2000 | 142 | 2000 |
| Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy S Hartmann, HJ Möbius International clinical psychopharmacology 18 (2), 81-85, 2003 | 141 | 2003 |
| Orthogonal triplet probes: an efficient method for unbiased estimation of length and surface of objects with unknown orientation in space T Mattfeldt, HJ Möbius, G Mall Journal of microscopy 139 (3), 279-289, 1985 | 140 | 1985 |
| Is it time to revise the diagnostic criteria for apathy in brain disorders P Robert, KL Lanctôt, L Agüera-Ortiz, P Aalten, F Bremond, ... The 2018 international consensus group. Eur Psychiatry 2018; 54: 71 76, 2018 | 111 | 2018 |
| Diagnostic criteria for apathy in neurocognitive disorders DS Miller, P Robert, L Ereshefsky, L Adler, D Bateman, J Cummings, ... Alzheimer's & Dementia 17 (12), 1892-1904, 2021 | 100 | 2021 |
| Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors HJ Moebius US Patent App. 10/691,895, 2004 | 90 | 2004 |
| Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer’s disease R Doody, Y Wirth, F Schmitt, HJ Möbius Dementia and geriatric cognitive disorders 18 (2), 227-232, 2004 | 79 | 2004 |
| Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke R Urfer, HJ Moebius, D Skoloudik, E Santamarina, W Sato, S Mita, ... Stroke 45 (11), 3304-3310, 2014 | 74 | 2014 |
| Memantine in moderately severe to severe Alzheimer's disease (AD): results of a placebo-controlled 6-month trial B Reisberg, U Windscheif, SH Ferris, VN Hingorani, A Stoeffler, ... Neurobiology of Aging, 275, 2000 | 73 | 2000 |
